Wedbush Ignites Pyxis Oncology with Bullish Rating — 215% Upside Ahead?
Wedbush rates Pyxis “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs.
/ 185 items
#XY Analyst Up/Down↓
ITK Pipeline Spotlight: Guggenheim Initiates Buy on Aclaris Therapeutics
Guggenheim rates ACRS Buy, $12 target vs $4.50 now; skin/immune drugs, trials ahead, big upside if results are good.
Citizens Bullish on Biomea: Could This Pill Actually Fix Diabetes?
Biomea is testing a new diabetes pill that may fix insulin cells. Early results look strong, with big growth potential but high risk.
“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
Guggenheim Slaps Buy Rating on CRBP: $45 Target Signals Massive Upside
Corbus Pharmaceuticals gets Buy rating ($45 target). Drug CRB-701 shows strong cancer results, safer than rivals. Stock down 43% may be opportunity.
Craig-Hallum Initiates Strong Buy on Spruce Biosciences with $140 Price Target as TA-ERT Advances Toward Approval
Spruce Biosciences has a rare disease drug (TA-ERT) showing strong results, FDA path clear, big sales and upside potential.